Receive our newsletter – data, insights and analysis delivered to you
July 2, 2009

J&J and Elan Join Forces on Alzheimer’s Immunotherapy Program

Johnson & Johnson (J&J) and Elan have signed an agreement to research, develop and commercialise selective products for the treatment and prevention of neurodegenerative conditions including Alzheimer's disease. As per the agreement J&J (through a newly formed company) will ac

By cms admin

Johnson & Johnson (J&J) and Elan have signed an agreement to research, develop and commercialise selective products for the treatment and prevention of neurodegenerative conditions including Alzheimer’s disease.

As per the agreement J&J (through a newly formed company) will acquire all the assets and rights of Elan related to its Alzheimer’s Immunotherapy Program (AIP).

J&J will in turn invest $1bn in Elan in exchange for newly issued American Depositary Receipts of Elan, representing 18.4% of Elan’s outstanding ordinary shares.

J&J will continue Elan’s activities with Wyeth under the AIP, and will initially commit up to $500m to continue the development and launch activities of bapineuzumab, as well as other compounds.

In return for the transfer rights and assets, Elan will receive a 49.9% equity interest in the newly formed J&J company, which will acquire the AIP.

Elan will then be entitled to a 49.9% share of the profits and certain royalty payments on the commercialisation of products, under the collaboration with Wyeth.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU